Equities analysts expect that Sarepta Therapeutics Inc (NASDAQ:SRPT) will report sales of $70.93 million for the current quarter, Zacks Investment Research reports. Nine analysts have made estimates for Sarepta Therapeutics’ earnings, with estimates ranging from $69.00 million to $73.22 million. Sarepta Therapeutics posted sales of $35.01 million in the same quarter last year, which suggests a positive year-over-year growth rate of 102.6%. The company is expected to announce its next earnings report on Wednesday, July 18th.
According to Zacks, analysts expect that Sarepta Therapeutics will report full-year sales of $298.22 million for the current fiscal year, with estimates ranging from $285.40 million to $308.66 million. For the next year, analysts expect that the business will report sales of $436.01 million per share, with estimates ranging from $362.54 million to $519.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Sarepta Therapeutics.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Thursday, May 3rd. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.23). Sarepta Therapeutics had a negative net margin of 83.88% and a negative return on equity of 24.68%. The business had revenue of $64.60 million for the quarter, compared to the consensus estimate of $65.31 million. During the same period in the prior year, the business posted ($0.57) EPS. Sarepta Therapeutics’s revenue for the quarter was up 295.3% on a year-over-year basis.
Shares of NASDAQ SRPT traded down $0.31 on Friday, reaching $137.73. 656,496 shares of the company’s stock traded hands, compared to its average volume of 1,646,908. Sarepta Therapeutics has a 12 month low of $32.80 and a 12 month high of $176.50. The company has a market capitalization of $9.04 billion, a price-to-earnings ratio of -83.93 and a beta of 1.34. The company has a debt-to-equity ratio of 0.55, a quick ratio of 12.28 and a current ratio of 13.37.
In related news, Director Richard Barry sold 75,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 27th. The shares were sold at an average price of $130.34, for a total value of $9,775,500.00. Following the sale, the director now owns 3,170,432 shares in the company, valued at $413,234,106.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.90% of the company’s stock.
A number of hedge funds have recently modified their holdings of SRPT. Element Capital Management LLC purchased a new stake in Sarepta Therapeutics in the fourth quarter worth approximately $17,706,000. Frontier Capital Management Co. LLC purchased a new stake in Sarepta Therapeutics in the first quarter worth approximately $16,940,000. JPMorgan Chase & Co. boosted its holdings in Sarepta Therapeutics by 36.3% in the first quarter. JPMorgan Chase & Co. now owns 709,070 shares of the biotechnology company’s stock worth $52,535,000 after purchasing an additional 188,841 shares during the last quarter. Franklin Resources Inc. purchased a new position in shares of Sarepta Therapeutics during the 1st quarter worth $9,209,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Sarepta Therapeutics during the 1st quarter worth $8,295,000. Institutional investors own 86.27% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.